LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Article: Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.

    Notini, Giulia / Naldini, Matteo Maria / Sica, Lorenzo / Viale, Giulia / Rognone, Alessia / Zambelli, Stefania / Zucchinelli, Patrizia / Piras, Marta / Bosi, Carlo / Mariani, Marco / Aldrighetti, Daniela / Bianchini, Giampaolo / Licata, Luca

    Frontiers in oncology

    2024  Volume 14, Page(s) 1374547

    Abstract: Background: Nausea and vomiting are common side effects of Trastuzumab Deruxtecan (T-DXd), but guidelines for optimal management were not initially available. This retrospective single-center study aimed at evaluating the efficacy of two antiemetic ... ...

    Abstract Background: Nausea and vomiting are common side effects of Trastuzumab Deruxtecan (T-DXd), but guidelines for optimal management were not initially available. This retrospective single-center study aimed at evaluating the efficacy of two antiemetic regimens in patients receiving T-DXd.
    Methods: Data from metastatic breast cancer patients receiving T-DXd were collected. Two groups were defined: patients treated with 5-HT3 receptor antagonists (RA) ± dexamethasone (5-HT3-group) and patients treated with a fixed oral combination of netupitant (NK1RA) and palonosetron ± dexamethasone (NK1 group). Physicians preferentially offered the NK1 regimen to patients at higher risk of nausea and vomiting based on internal recommendations. Only nausea and vomiting during cycles 1 and 2 were considered. Comparisons of nausea and vomiting by the antiemetic prophylaxis group were assessed using chi-square.
    Results: A total of 53 patients were included in the analysis. At cycle 1, 72% and 28% of patients received the 5-HT3 and NK1 prophylaxis, respectively. Overall, 58% reported nausea, with no differences between groups (58% vs. 60%;
    Conclusions: The NK1 regimen improved vomiting control at cycle 1 and, when introduced at cycle 2, significantly improved both nausea and vomiting. The biased NK1 selection for higher-risk patients may have dampened the differences between groups at cycle 1. These findings support enhanced control of T-DXd-related nausea and vomiting with NK1RA.
    Language English
    Publishing date 2024-03-11
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2024.1374547
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Weekly Paclitaxel Administered During a Twin Pregnancy for Recurrent Breast Cancer: Case Report and Review of the Literature.

    Girardelli, Serena / Rabaiotti, Emanuela / Mauro, Fabio / Gentilini, Oreste / Zucchinelli, Patrizia / Cioffi, Raffaella / Valsecchi, Luca / Mangili, Giorgia / Peccatori, Fedro A / Candiani, Massimo

    Journal of adolescent and young adult oncology

    2022  Volume 11, Issue 6, Page(s) 632–636

    Abstract: Although cancer treatment during single pregnancy has been standardized, how to manage cancer diagnosed during a multiple gestation is still unclear. Chemotherapy during pregnancy has shown to be safe, however, there are reports of increased risks of ... ...

    Abstract Although cancer treatment during single pregnancy has been standardized, how to manage cancer diagnosed during a multiple gestation is still unclear. Chemotherapy during pregnancy has shown to be safe, however, there are reports of increased risks of fetal complications such as intrauterine growth restriction and preterm birth. Also, how to best adjust this to the pharmacokinetic characteristics of a twin gestation has yet to be fully investigated. We report the case of an IVF twin pregnancy with a diagnosis of breast cancer recurrence shortly after conception, and how the pregnancy was managed to obtain optimal obstetric, maternal/oncological, and fetal outcomes.
    MeSH term(s) Infant, Newborn ; Humans ; Female ; Pregnancy, Twin ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Breast Neoplasms/drug therapy ; Premature Birth
    Chemical Substances Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2022-02-18
    Publishing country United States
    Document type Review ; Case Reports ; Journal Article
    ZDB-ID 2607978-1
    ISSN 2156-535X ; 2156-5333
    ISSN (online) 2156-535X
    ISSN 2156-5333
    DOI 10.1089/jayao.2021.0181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.

    Viale, Giulia / Licata, Luca / Sica, Lorenzo / Zambelli, Stefania / Zucchinelli, Patrizia / Rognone, Alessia / Aldrighetti, Daniela / Di Micco, Rosa / Zuber, Veronica / Pasetti, Marcella / Di Muzio, Nadia / Rodighiero, Mariagrazia / Panizza, Pietro / Sassi, Isabella / Petrella, Giovanna / Cascinu, Stefano / Gentilini, Oreste Davide / Bianchini, Giampaolo

    The oncologist

    2020  Volume 25, Issue 7, Page(s) e1013–e1020

    Abstract: Northern Italy has been one of the European regions reporting the highest number of COVID-19 cases and deaths. The pandemic spread has challenged the National Health System, requiring reallocation of most of the available health care resources to treat ... ...

    Abstract Northern Italy has been one of the European regions reporting the highest number of COVID-19 cases and deaths. The pandemic spread has challenged the National Health System, requiring reallocation of most of the available health care resources to treat COVID-19-positive patients, generating a competition with other health care needs, including cancer. Patients with cancer are at higher risk of developing critical illness after COVID-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all patients with cancer. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this article, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the COVID-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited health care resources. IMPLICATIONS FOR PRACTICE: Managing patients with breast cancer during the COVID-19 outbreak is challenging. The present work highlights the need to estimate the individual patient risk of infection, which depends on both epidemiological considerations and individual clinical characteristics. The management of patients with breast cancer should be adapted and personalized according to the balance between COVID-19-related risk and the expected benefit of treatments. This work also provides useful suggestions on the modality of patient triage, the conduct of clinical trials, the management of an oncologic team, and the approach to patients' and health workers' psychological distress.
    MeSH term(s) Adult ; Age Factors ; Aged ; Betacoronavirus/pathogenicity ; Breast Neoplasms/therapy ; COVID-19 ; Clinical Trials as Topic/organization & administration ; Clinical Trials as Topic/standards ; Continuity of Patient Care/organization & administration ; Continuity of Patient Care/standards ; Coronavirus Infections/epidemiology ; Coronavirus Infections/prevention & control ; Coronavirus Infections/transmission ; Coronavirus Infections/virology ; Female ; Humans ; Infection Control/organization & administration ; Infection Control/standards ; Italy/epidemiology ; Medical Oncology/organization & administration ; Medical Oncology/standards ; Middle Aged ; Pandemics/prevention & control ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/prevention & control ; Pneumonia, Viral/transmission ; Pneumonia, Viral/virology ; Research Design/standards ; Risk Assessment ; Risk Factors ; SARS-CoV-2 ; Telemedicine/organization & administration ; Telemedicine/standards
    Keywords covid19
    Language English
    Publishing date 2020-05-26
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1634/theoncologist.2020-0316
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Antiangiogenic strategies in breast cancer management.

    Giovannini, Monica / Aldrighetti, Daniela / Zucchinelli, Patrizia / Belli, Carmen / Villa, Eugenio

    Critical reviews in oncology/hematology

    2010  Volume 76, Issue 1, Page(s) 13–35

    Abstract: Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular ...

    Abstract Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far.
    MeSH term(s) Angiogenesis Inhibitors/pharmacology ; Angiogenesis Inhibitors/therapeutic use ; Animals ; Breast Neoplasms/drug therapy ; Female ; Humans ; Neovascularization, Pathologic/drug therapy
    Chemical Substances Angiogenesis Inhibitors
    Language English
    Publishing date 2010-10
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 605680-5
    ISSN 1879-0461 ; 0737-9587 ; 1040-8428
    ISSN (online) 1879-0461
    ISSN 0737-9587 ; 1040-8428
    DOI 10.1016/j.critrevonc.2009.12.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1931: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID ‐19 Outbreak

    Viale, Giulia / Licata, Luca / Sica, Lorenzo / Zambelli, Stefania / Zucchinelli, Patrizia / Rognone, Alessia / Aldrighetti, Daniela / Di Micco, Rosa / Zuber, Veronica / Pasetti, Marcella / Di Muzio, Nadia / Rodighiero, Mariagrazia / Panizza, Pietro / Sassi, Isabella / Petrella, Giovanna / Cascinu, Stefano / Gentilini, Oreste Davide / Bianchini, Giampaolo

    The Oncologist

    2020  Volume 25, Issue 7

    Keywords Cancer Research ; Oncology ; covid19
    Language English
    Publisher Alphamed Press
    Publishing country us
    Document type Article ; Online
    ZDB-ID 1409038-7
    ISSN 1083-7159
    ISSN 1083-7159
    DOI 10.1634/theoncologist.2020-0316
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID ‐19 Outbreak

    Viale, Giulia / Licata, Luca / Sica, Lorenzo / Zambelli, Stefania / Zucchinelli, Patrizia / Rognone, Alessia / Aldrighetti, Daniela / Di Micco, Rosa / Zuber, Veronica / Pasetti, Marcella / Di Muzio, Nadia / Rodighiero, Mariagrazia / Panizza, Pietro / Sassi, Isabella / Petrella, Giovanna / Cascinu, Stefano / Gentilini, Oreste Davide / Bianchini, Giampaolo

    The Oncologist

    2020  Volume 25, Issue 7

    Keywords Cancer Research ; Oncology ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    ZDB-ID 1409038-7
    ISSN 1083-7159
    ISSN 1083-7159
    DOI 10.1634/theoncologist.2020-0316
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak

    Viale, Giulia / Licata, Luca / Sica, Lorenzo / Zambelli, Stefania / Zucchinelli, Patrizia / Rognone, Alessia / Aldrighetti, Daniela / Di Micco, Rosa / Zuber, Veronica / Pasetti, Marcella / Di Muzio, Nadia / Rodighiero, Mariagrazia / Panizza, Pietro / Sassi, Isabella / Petrella, Giovanna / Cascinu, Stefano / Gentilini, Oreste Davide / Bianchini, Giampaolo

    Oncologist

    Abstract: Northern Italy has been one of the European regions reporting the highest number of COVID-19 cases and deaths. The pandemic spread has challenged the National Health System, requiring reallocation of most of the available health care resources to treat ... ...

    Abstract Northern Italy has been one of the European regions reporting the highest number of COVID-19 cases and deaths. The pandemic spread has challenged the National Health System, requiring reallocation of most of the available health care resources to treat COVID-19-positive patients, generating a competition with other health care needs, including cancer. Patients with cancer are at higher risk of developing critical illness after COVID-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all patients with cancer. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this article, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the COVID-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited health care resources. IMPLICATIONS FOR PRACTICE: Managing patients with breast cancer during the COVID-19 outbreak is challenging. The present work highlights the need to estimate the individual patient risk of infection, which depends on both epidemiological considerations and individual clinical characteristics. The management of patients with breast cancer should be adapted and personalized according to the balance between COVID-19-related risk and the expected benefit of treatments. This work also provides useful suggestions on the modality of patient triage, the conduct of clinical trials, the management of an oncologic team, and the approach to patients' and health workers' psychological distress.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #506429
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.

    Giotta, Francesco / Acito, Luigi / Candeloro, Giampiero / Del Medico, Pietro / Gadaleta-Caldarola, Gennaro / Giordano, Guido / Gueli, Rossana / Lugini, Antonio / Magri, Valentina / Mandarà, Marta / Masci, Giovanna / Pisconti, Salvatore / Pistelli, Mirco / Rizzi, Anna / Salesi, Nello / Schirone, Alessio / Scognamiglio, Giovanni / Tedeschi, Maria / Zucchinelli, Patrizia

    The oncologist

    2016  Volume 21, Issue 11, Page(s) 1298–1305

    Abstract: Background: Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use ... ...

    Abstract Background: Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use or eribulin in this setting.
    Patients and methods: Patients were retrospectively identified in 19 reference centers. All patients received eribulin treatment, according to the standard practice of each center. Data on the identified patients were collected using a standardized form and were then centrally reviewed by two experienced oncologists.
    Results: A total of 23 patients (median age, 64 years; range, 42-80) were considered. The median age at the time of diagnosis of breast cancer was 57 years (range, 42-74). HER2 status was negative in 14 patients (61%), and 2 patients (9%) had triple-negative disease. The most common metastatic sites were the lung (
    Conclusion: Although hampered by all the limitations of any retrospective case series, the results of the present study suggest, for the first time, the use of eribulin as therapy for male breast cancer.
    Implications for practice: Evidence on the management and treatment of male breast cancer is eagerly awaited. Although hampered by all the limitations of any retrospective case series, the results of the present study suggest, for the first time, the use of eribulin as therapy for male breast cancer.
    Language English
    Publishing date 2016-10-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1634/theoncologist.2016-0022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Mediastinal follicular dendritic cell sarcoma.

    Ceresoli, Giovanni Luca / Zucchinelli, Patrizia / Ponzoni, Maurilio / Gregorc, Vanesa / Bencardino, Katia / Paties, Carlo Terenzio

    Haematologica

    2003  Volume 88, Issue 2, Page(s) ECR04

    MeSH term(s) Adult ; Dendritic Cells, Follicular/pathology ; Fatal Outcome ; Humans ; Male ; Mediastinal Neoplasms/diagnosis ; Mediastinal Neoplasms/pathology ; Mediastinal Neoplasms/therapy ; Neoplasms, Second Primary/pathology ; Neoplasms, Second Primary/therapy ; Sarcoma/diagnosis ; Sarcoma/pathology ; Sarcoma/therapy ; Thyroid Neoplasms/pathology ; Thyroid Neoplasms/surgery
    Language English
    Publishing date 2003-02
    Publishing country Italy
    Document type Case Reports ; Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0390-6078 ; 0017-6567
    ISSN (online) 1592-8721
    ISSN 0390-6078 ; 0017-6567
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.76: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top